Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum

Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea

Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024

SAN FRANCISCO, CA / ACCESSWIRE / October 12, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present and host one-on-one meetings with investors during the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023, and on October 18, 2023 at the in-person BIO Investor Forum.

Participation Instructions for Jaguar Health Presentation at the Lytham Partners Fall 2023 Investor Conference

Company Webcast: Jaguar Health's webcast presentation will be available for viewing at 7:00 AM Eastern on Tuesday, October 17, 2023, at https://wsw.com/webcast/lytham9/jagx/2033040. The webcast will also be archived and available for replay.

1x1 Meetings: Ms. Conte will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [e-mail] or register at https://www.lythampartners.com/fall2023invreg/.

Participation Instructions for Jaguar Health Presentation at the BIO Investor Forum

When: Wednesday, October 18, 2023 from 11:45 AM - 12:00 PM Pacific

Where: Franciscan C room on the Ballroom Level of the Hilton San Francisco Union Square, San Francisco, CA

Registration link for conference: Click Here

As recently announced by Napo Pharmaceuticals (Napo), a Jaguar family company, the last patient has completed their final visit for the stage 1 primary endpoint treatment period of Napo's pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy. This trial is studying an indication Napo also refers to as preventive treatment of chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as chronic debilitating diarrhea (loose and/or watery stools), urgency, and bowel incontinence.